Topic Overview > The new GATA antibody

The new GATA antibody

A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC. (Di Ai et al.; "TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34: 710-719, 2021)

Products

Products may not be approved or available in your region. Please check with your local Zytomed-Systems representative.
Product Clone Order no.
Host Rabbit
Clone ZR382
Format Concentrate
Reactivity -
Method P
Positive control Normal breast, breast carcinoma
Dilution 1:100 - 1:200
Isotype IgG
Immunogen Synthesized peptide corresponding to the C-terminus of human TRPS1 protein
Localization Nuclear
TRPS1 		ZR382 Z2673RL
Host Rabbit
Clone ZR382
Format Concentrate
Reactivity -
Method P
Positive control Normal breast, breast carcinoma
Dilution 1:100 - 1:200
Isotype IgG
Immunogen Synthesized peptide corresponding to the C-terminus of human TRPS1 protein
Localization Nuclear
TRPS1 		ZR382 Z2673RS
Host Rabbit
Clone ZR382
Format Concentrate
Reactivity -
Method P
Positive control Normal breast, breast carcinoma
Dilution 1:100 - 1:200
Isotype IgG
Immunogen Synthesized peptide corresponding to the C-terminus of human TRPS1 protein
Localization Nuclear
TRPS1 		ZR382 Z2673RT
Host Rabbit
Clone ZR382
Format r-t-u
Reactivity -
Method P
Positive control Normal breast, breast carcinoma
Dilution gebrauchsfertig
Isotype IgG
Immunogen Synthesized peptide corresponding to the C-terminus of human TRPS1 protein
Localization Nuclear
TRPS1 		ZR382 Z2673RP

Documents

New GATA Antibody

Download

Back to overview

Further topics

Now available: The AmoyDx® Myeloid Blood Cancer Panel

The AmoyDx® Myeloid Blood Cancer Panel enables a comprehensive molecular genetic analysis for the qualitative detection of SNVs, InDels and fusions in 55 genes associated with myeloid leukemia on DNA and RNA.

IVDR Update October 2022

As a manufacturer and distributor of in vitro diagnostics, our enterprise group with the companies Zytomed Systems GmbH and ZytoVision GmbH attaches great importance to the timely implementation of the requirements of the IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5th 2017 on in vitro diagnostic medical devices).

Products

Topics

Learning videos

Downloads

Company

Distributors

Privacy Imprint
DE EN